spacer
home > > autumn 2009 > thoughtful testing
PUBLICATIONS


Thoughtful Testing

 

The European Medicines Agency (EMEA) is a decentralised body of the EU. Its main responsibility is the safety and promotion of public health, through the evaluation and supervision of medicines for human use. The EMEA holds responsibility for the scientific evaluation of applications for European marketing authorisation of medicinal products (1).

NEW GUIDELINES

On 1st February 2009, the EMEA released new guidelines for companies developing medicines for the treatment of Alzheimer’s disease (AD) and other dementias, and for Parkinson’s disease, in the light of recent scientific progression in the understanding of these diseases and conditions (2). The document itself is offered as general guidance on the development of medicinal products for the treatment of dementia and its subtypes. It does not replace other EMEA and ICH guidelines, but rather works in collaboration with them.

The advances over the past few years in both clinical science and molecular biology have contributed to an emphasis on and growing interest in the development of more valuable symptomatic or disease-modifying treatments, such as early treatments that could prevent the emergence or even slow the progression of a disease. These guidelines have been developed to assist companies developing such medicines on appropriate clinical trial designs (2).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer

Helen Brooker began working for CDR Ltd in March 2008 and is an active member of the R&D team. She graduated with a first class honours degree in 2006 and went on to be involved in numerous research projects. She is currently embarking on her MSc in Psychology. Helen is the R&D project manger and manages the CDR Collaborative Research programme, where she works with key medical institutions and universities across the globe. She works closely with the expanding scientific development team as well as providing scientific support to business development.

spacer
Helen Brooker
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Glatt Selected for GMP Biorefinery Engineering Project by NSTDA in Thailand

Bangkok, Thailand and Weimar, Germany – September 2020: National Science and Technology Development Agency Thailand (NSTDA) is implementing the Government’s Thailand 4.0 initiative to promote strategic biotechnology growth at the country’s Eastern Economic Corridor of Innovation (EECi). One part of this new BIOPOLIS complex is the GMP Biorefinery Pilot Plant at EECi, for which German engineering company Glatt Ingenieurtechnik was selected to provide the engineering services. The contract between NSTDA and Glatt comprises the Conceptual and Basic Design phases for the GMP Biorefinery.
More info >>

White Papers

R&D to Product: How to Reduce Costly Scale-Up Problems

Natoli Engineering Company, Inc.

When scaling a new drug formulation from the development side of R&D into manufacturing, there is often a reality check with respect to process scaleup and performance of the formulation at production levels. Problems with capping/lamination and sticking/ picking are often first realized when a formulation is introduced to a level of compression required to supply market demand.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement